このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

WB-EMS and Diet Effects on Body Composition, Cardiometabolic Markers, and Myokines in Obese Women

2026年6月26日 更新者：Murat Açık、Firat University

Effects of an Eight-Week Whole-Body Electromyostimulation and Diet Program on Body Composition, Cardiometabolic Markers, and the Myokines Irisin and Betatrophin in Women With Obesity: A Randomized Controlled Trial

This randomized controlled trial investigated the effects of an 8-week whole-body electromyostimulation (WB-EMS) combined with a hypocaloric diet on body composition, cardiometabolic markers, and serum levels of the myokines irisin and betatrophin (ANGPTL8) in women with obesity. Participants were randomly assigned to either a diet-only group or a diet plus WB-EMS group. WB-EMS sessions were conducted twice weekly (20-25 minutes per session) over 8 weeks. The primary outcomes included BMI, body fat percentage, lean body mass, fasting blood glucose, insulin, HOMA-IR, HbA1c, lipid profile, CRP, and serum irisin and betatrophin concentrations. The study aimed to evaluate whether WB-EMS adds metabolic and myokine-related benefits beyond those achieved by dietary restriction alone in obese women.

調査の概要

状態

完了

条件

介入・治療

詳細な説明

This study was a randomized controlled trial (RCT) designed to investigate the effects of an 8-week whole-body electromyostimulation (WB-EMS) combined with a hypocaloric diet on body composition, cardiometabolic markers, and serum levels of the myokines irisin and betatrophin (ANGPTL8) in women with obesity.

Participants were randomly assigned to one of two groups: (1) Diet-only group (control): received a hypocaloric diet prescription without exercise training; (2) WB-EMS + Diet group (intervention): received the same hypocaloric diet plus WB-EMS training sessions conducted twice weekly (20-25 minutes per session) over 8 weeks.

Body composition assessments included body weight, BMI, body fat percentage, fat mass, fat-free mass, and waist circumference, measured using multifrequency bioelectrical impedance analysis (InBody 270). Cardiometabolic markers assessed included fasting blood glucose, serum insulin, HOMA-IR, HbA1c, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, blood pressure, and C-reactive protein (CRP). Serum irisin and betatrophin concentrations were measured at baseline and post-intervention using ELISA.

The primary aim was to evaluate whether WB-EMS combined with dietary restriction provides additional metabolic and myokine-related benefits beyond those achieved by dietary restriction alone in obese women.

研究の種類

介入

入学 (実際)

44

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Adult women aged 18-65 years
  • BMI >= 30 kg/m2 (obesity)
  • Sedentary lifestyle (no regular physical activity for the past 6 months)
  • Willingness to participate and provide written informed consent

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Cardiovascular disease, neurological disorders, or implanted pacemaker/defibrillator
  • Active cancer or ongoing chemotherapy/radiotherapy
  • Use of medications affecting body weight or metabolic parameters
  • Prior WB-EMS training experience
  • Skin conditions contraindicating electrode use

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか？

デザインの詳細

  • 主な目的：処理
  • 割り当て：ランダム化
  • 介入モデル：並列代入
  • マスキング：なし（オープンラベル）

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ：Diet Only
Participants received an 8-week individualized hypocaloric diet program only. The diet was prescribed based on the Mifflin-St. Jeor equation with a 500 kcal/day deficit.
行動：Hypocaloric Diet
An individualized hypocaloric diet with a 500 kcal/day deficit calculated using the Mifflin-St. Jeor equation, prescribed to both study arms for 8 weeks.
実験的：Diet + WB-EMS
Participants received an 8-week individualized hypocaloric diet program combined with whole-body electromyostimulation (WB-EMS) training. The diet was prescribed based on the Mifflin-St. Jeor equation with a 500 kcal/day deficit. WB-EMS sessions were performed twice per week for 20 minutes using a full-body electrostimulation suit.
行動：Hypocaloric Diet
An individualized hypocaloric diet with a 500 kcal/day deficit calculated using the Mifflin-St. Jeor equation, prescribed to both study arms for 8 weeks.
デバイス：Whole-Body Electromyostimulation (WB-EMS)
WB-EMS training was performed twice per week for 8 weeks, with 20-minute sessions using a full-body electrostimulation suit. Stimulation parameters: frequency 85 Hz, pulse width 350 µs, intermittent mode (4 s on / 4 s off), with simultaneous dynamic exercises.

この研究は何を測定していますか？

主要な結果の測定

結果測定
メジャーの説明
時間枠
Body Weight
時間枠：8 weeks (baseline to post-intervention)
Changes in body weight (kg) measured by multifrequency bioelectrical impedance analyser (InBody 270) from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
Body Mass Index (BMI)
時間枠：8 weeks (baseline to post-intervention)
Changes in body mass index (BMI, kg/m²) measured by multifrequency bioelectrical impedance analyser (InBody 270) from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
Body Fat Percentage
時間枠：8 weeks (baseline to post-intervention)
Changes in body fat percentage (%) measured by multifrequency bioelectrical impedance analyser (InBody 270) from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
Fat Mass
時間枠：8 weeks (baseline to post-intervention)
Changes in fat mass (kg) measured by multifrequency bioelectrical impedance analyser (InBody 270) from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
Fat-Free Mass (Lean Body Mass)
時間枠：8 weeks (baseline to post-intervention)
Changes in fat-free mass / lean body mass (kg) measured by multifrequency bioelectrical impedance analyser (InBody 270) from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
Waist Circumference
時間枠：8 weeks (baseline to post-intervention)
Changes in waist circumference (cm) measured by standard anthropometric tape from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)

二次結果の測定

結果測定
メジャーの説明
時間枠
Fasting Blood Glucose (FBG)
時間枠：8 weeks (baseline to post-intervention)
Changes in fasting blood glucose (mg/dL) measured by standard automated clinical chemistry platform from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
Serum Insulin
時間枠：8 weeks (baseline to post-intervention)
Changes in serum insulin (µIU/mL) measured by immunoassay platform from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
HOMA-IR (Insulin Resistance)
時間枠：8 weeks (baseline to post-intervention)
Changes in HOMA-IR (calculated as fasting insulin x fasting glucose / 405) from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
Glycated Haemoglobin (HbA1c)
時間枠：8 weeks (baseline to post-intervention)
Changes in HbA1c (%) measured by immunoassay platform from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
Total Cholesterol (TC)
時間枠：8 weeks (baseline to post-intervention)
Changes in total cholesterol (mg/dL) measured by standard automated clinical chemistry platform from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
Triglycerides (TG)
時間枠：8 weeks (baseline to post-intervention)
Changes in serum triglycerides (mg/dL) measured by standard automated clinical chemistry platform from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
LDL Cholesterol (LDL-C)
時間枠：8 weeks (baseline to post-intervention)
Changes in LDL cholesterol (mg/dL) measured by standard automated clinical chemistry platform from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
HDL Cholesterol (HDL-C)
時間枠：8 weeks (baseline to post-intervention)
Changes in HDL cholesterol (mg/dL) measured by standard automated clinical chemistry platform from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
C-Reactive Protein (CRP)
時間枠：8 weeks (baseline to post-intervention)
Changes in serum C-reactive protein (mg/L) measured by high-sensitivity immunoassay from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
Serum Irisin
時間枠：8 weeks (baseline to post-intervention)
Changes in serum irisin levels (ng/mL) measured by ELISA from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
Serum Betatrophin (ANGPTL8)
時間枠：8 weeks (baseline to post-intervention)
Changes in serum betatrophin (ANGPTL8) levels (ng/mL) measured by ELISA from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
Systolic Blood Pressure
時間枠：8 weeks (baseline to post-intervention)
Changes in systolic blood pressure (mmHg) measured by sphygmomanometer after 10 minutes of rest from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
Diastolic Blood Pressure
時間枠：8 weeks (baseline to post-intervention)
Changes in diastolic blood pressure (mmHg) measured by sphygmomanometer after 10 minutes of rest from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

Firat University

協力者

Dicle University

捜査官

  • スタディディレクター：Fazilet Erman, Dr、Firat University
  • スタディディレクター：Feray Cagiran Yilmaz, Dr、Dicle University
  • スタディディレクター：Esra Das, Msc、Firat University

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年5月1日

一次修了 (実際)

2026年3月1日

研究の完了 (実際)

2026年3月1日

試験登録日

最初に提出

2026年6月17日

QC基準を満たした最初の提出物

2026年6月26日

最初の投稿 (実際)

2026年6月30日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月30日

QC基準を満たした最後の更新が送信されました

2026年6月26日

最終確認日

2026年6月1日

詳しくは

本研究に関する用語

キーワード

追加の関連 MeSH 用語

その他の研究ID番号

  • FU_MAcik_WB-EMS_2025
  • 30456 (その他の識別子：Firat Univ. Non-Interventional Research Ethics Comm.)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Individual participant data will not be publicly shared due to institutional privacy policies.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する